Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 5/20 | 0.35 |
| ▸ | CYP21A2 | P08686 | 4/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6730354 | 1.00 | CYP17A1 (0.35) | CYP17A1CYP21A2CYP11B1ALDH1A1PDGFRB | |
| SCHEMBL6730350 | 0.85 | PDGFRB (0.31) | ALDH1A1PDGFRBPDGFRAKDM4EMEN1 | |
| SCHEMBL6729436 | 0.83 | F10 (0.33) | ALDH1A1KDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL6726791 | 0.83 | F10 (0.32) | ALDH1A1KDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL6726790 | 0.83 | F10 (0.32) | ALDH1A1KDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL6729435 | 0.83 | F10 (0.33) | ALDH1A1KDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL6726639 | 0.80 | CYP17A1 (0.39) | CYP17A1CYP21A2CYP11B1ALDH1A1PDGFRB | |
| SCHEMBL6726636 | 0.80 | CYP17A1 (0.39) | CYP17A1CYP21A2CYP11B1ALDH1A1PDGFRB | |
| SCHEMBL6728993 | 0.79 | ENPP2 (0.36) | ALDH1A1KDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL6781804 | 0.79 | ENPP2 (0.36) | ALDH1A1KDM4EMEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | CYP17A1 946/4885CYP21A2 584/4885CYP11B1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.